See more : MIGALO HOLDINGS Inc. (5535.T) Income Statement Analysis – Financial Results
Complete financial analysis of Standard BioTools Inc. (LAB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Standard BioTools Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Henderson High Income Trust plc (HHI.L) Income Statement Analysis – Financial Results
- Net One Systems Co., Ltd. (NONEF) Income Statement Analysis – Financial Results
- Somany Ceramics Limited (SOMANYCERA.NS) Income Statement Analysis – Financial Results
- PETRONAS Dagangan Berhad (PNADF) Income Statement Analysis – Financial Results
- Kkalpana Industries (India) Limited (KKALPANAIND.BO) Income Statement Analysis – Financial Results
Standard BioTools Inc. (LAB)
About Standard BioTools Inc.
Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Standard BioTools Inc. has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 106.34M | 97.95M | 130.58M | 138.14M | 117.24M | 112.96M | 101.94M | 104.45M | 114.71M | 116.46M | 71.18M | 52.33M | 42.87M | 33.56M | 25.41M | 15.35M | 7.28M | 6.40M | 130.58M |
| Cost of Revenue | 55.89M | 60.90M | 61.21M | 54.82M | 52.96M | 51.32M | 49.96M | 46.01M | 46.63M | 42.85M | 20.08M | 15.33M | 13.19M | 11.58M | 11.49M | 8.36M | 3.51M | 2.77M | 53.32M |
| Gross Profit | 50.45M | 37.05M | 69.37M | 83.33M | 64.28M | 61.65M | 51.98M | 58.44M | 68.08M | 73.61M | 51.10M | 37.01M | 29.67M | 21.98M | 13.93M | 6.98M | 3.76M | 3.63M | 77.27M |
| Gross Profit Ratio | 47.44% | 37.83% | 53.13% | 60.32% | 54.83% | 54.57% | 50.99% | 55.95% | 59.35% | 63.21% | 71.79% | 70.72% | 69.23% | 65.49% | 54.80% | 45.50% | 51.70% | 56.66% | 59.17% |
| Research & Development | 25.95M | 38.50M | 37.94M | 36.46M | 31.64M | 30.03M | 30.83M | 38.42M | 39.26M | 43.42M | 19.73M | 16.60M | 13.94M | 13.01M | 12.32M | 14.02M | 14.39M | 15.59M | 37.94M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 87.54M | 114.76M | 98.89M | 97.90M | 84.48M | 79.78M | 79.52M | 93.21M | 82.96M | 71.32M | 48.06M | 38.48M | 31.30M | 23.55M | 19.65M | 22.51M | 12.90M | 9.70M | 98.89M |
| Other Expenses | 0.00 | -12.31M | 7.63M | 507.00K | 1.43M | 637.00K | 385.00K | -1.17M | -1.16M | -857.00K | 502.00K | -189.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.89M |
| Operating Expenses | 113.49M | 153.26M | 136.83M | 134.36M | 116.12M | 109.81M | 110.34M | 131.63M | 122.22M | 114.75M | 67.79M | 55.08M | 45.24M | 36.55M | 31.96M | 36.53M | 27.29M | 25.29M | 144.73M |
| Cost & Expenses | 169.38M | 214.15M | 198.04M | 189.18M | 169.08M | 161.13M | 160.30M | 177.64M | 168.85M | 157.60M | 87.87M | 70.41M | 58.43M | 48.13M | 43.45M | 44.89M | 30.80M | 28.06M | 198.04M |
| Interest Income | 0.00 | 4.33M | 291.00K | 307.00K | 1.33M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.00K | 37.00K | 766.00K | 1.14M | 565.00K | 0.00 |
| Interest Expense | 4.57M | 4.33M | 3.82M | 3.57M | 4.28M | 13.89M | 5.82M | 5.82M | 5.81M | 5.34M | 14.00K | 628.00K | 3.10M | 2.16M | 2.88M | 2.03M | 2.79M | 2.26M | -3.82M |
| Depreciation & Amortization | 15.18M | 15.03M | 16.07M | 17.94M | 15.81M | 16.50M | 18.30M | 17.94M | 16.12M | 4.06M | 2.55M | 1.48M | 1.06M | 1.50M | 1.94M | 1.97M | 2.14M | 1.46M | 0.00 |
| EBITDA | -54.46M | -173.57M | -43.77M | -34.61M | -46.62M | -31.03M | -39.68M | -56.42M | -32.87M | -38.50M | -13.82M | -16.78M | -18.14M | -13.52M | -14.67M | -26.12M | -20.91M | -19.83M | -67.46M |
| EBITDA Ratio | -51.21% | -115.87% | -33.89% | -25.05% | -29.51% | -27.40% | -38.62% | -54.02% | -34.16% | -32.58% | -19.15% | -32.06% | -33.84% | -38.92% | -63.20% | -174.69% | -278.32% | -306.96% | -51.66% |
| Operating Income | -76.60M | -116.21M | -67.46M | -51.04M | -51.84M | -48.16M | -58.36M | -73.19M | -50.16M | -51.84M | -17.95M | -18.07M | -18.57M | -14.57M | -18.04M | -29.54M | -23.53M | -21.66M | -67.46M |
| Operating Income Ratio | -72.03% | -118.64% | -51.66% | -36.94% | -44.22% | -42.64% | -57.25% | -70.07% | -43.72% | -44.51% | -25.22% | -34.53% | -43.31% | -43.42% | -70.98% | -192.50% | -323.38% | -338.59% | -51.66% |
| Total Other Income/Expenses | 2.40M | -76.72M | 3.80M | -3.07M | -14.87M | -13.26M | -5.44M | -6.99M | -4.64M | -5.87M | 2.26M | -817.00K | -3.74M | -2.25M | -1.14M | -103.00K | -1.82M | -1.89M | 3.80M |
| Income Before Tax | -74.20M | -192.93M | -63.66M | -54.10M | -66.71M | -61.42M | -63.80M | -80.18M | -54.79M | -57.71M | -15.69M | -18.89M | -22.30M | -16.82M | -19.18M | -29.65M | -25.35M | -23.55M | -63.66M |
| Income Before Tax Ratio | -69.78% | -196.97% | -48.75% | -39.16% | -56.89% | -54.37% | -62.59% | -76.76% | -47.76% | -49.55% | -22.03% | -36.09% | -52.03% | -50.12% | -75.47% | -193.17% | -348.40% | -368.13% | -48.75% |
| Income Tax Expense | 452.00K | -2.83M | -4.42M | -1.08M | -1.92M | -2.41M | -3.26M | -4.19M | -1.48M | -4.88M | 137.00K | 136.00K | 166.00K | 83.00K | -50.00K | -147.00K | 105.00K | 194.00K | -4.42M |
| Net Income | -74.66M | -190.10M | -59.24M | -53.02M | -64.79M | -59.01M | -60.54M | -75.99M | -53.32M | -52.83M | -15.82M | -19.02M | -22.47M | -16.90M | -19.13M | -29.50M | -25.45M | -23.55M | -59.24M |
| Net Income Ratio | -70.21% | -194.08% | -45.36% | -38.38% | -55.26% | -52.24% | -59.38% | -72.75% | -46.48% | -45.36% | -22.23% | -36.35% | -52.42% | -50.36% | -75.27% | -192.21% | -349.84% | -368.13% | -45.36% |
| EPS | -0.94 | -2.43 | -0.78 | -0.74 | -0.97 | -1.49 | -1.84 | -2.62 | -1.86 | -1.90 | -0.62 | -0.86 | -1.26 | -0.89 | -11.02 | -17.85 | -13.47 | -12.46 | 0.00 |
| EPS Diluted | -0.94 | -2.43 | -0.78 | -0.74 | -0.97 | -1.49 | -1.84 | -2.62 | -1.86 | -1.90 | -0.62 | -0.86 | -1.26 | -0.89 | -11.02 | -17.85 | -13.47 | -12.46 | 0.00 |
| Weighted Avg Shares Out | 79.16M | 78.31M | 75.79M | 72.04M | 66.78M | 39.65M | 32.98M | 29.01M | 28.71M | 27.77M | 25.48M | 22.14M | 17.85M | 18.98M | 1.74M | 1.65M | 1.89M | 1.89M | 0.00 |
| Weighted Avg Shares Out (Dil) | 79.16M | 78.31M | 75.79M | 72.04M | 66.78M | 39.65M | 32.98M | 29.01M | 28.71M | 27.77M | 25.48M | 22.14M | 17.85M | 18.98M | 1.74M | 1.65M | 1.89M | 1.89M | 0.00 |
Standard BioTools Inc. (LAB) Q4 2022 Earnings Call Transcript
Standard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2022 Financial Results
Broadridge Teams with SLIB to Deliver French Market Voting Solution for Global Investors
Standard BioTools Inc. (LAB) Q3 2022 Earnings Call Transcript
Standard BioTools Announces Conference Call and Webcast of Third Quarter 2022 Financial Results
Standard BioTools Inc. (LAB) CEO Michael Egholm on Q2 2022 Results - Earnings Call Transcript
Best Penny Stocks To Buy In August According To Insiders, 1 Bet Over $2 Million
Standard BioTools Announces Conference Call and Webcast of Second Quarter 2022 Financial Results
10 Top Penny Stocks To Buy In June According To These Insiders Part 1
Standard Bitola Inc. (LAB) CEO Michael Egholm on Q1 2022 Results - Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports